New research from the University of East Anglia and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.
Monthly Archives: February 2022
A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
Doing less exercise could deactivate a vital protein in the body, causing further inactivity and making exercise more difficult, new research suggests.
In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of three candidate vaccines, ED88, ED90, and ED94, to select the most appropriate one for future development.
In a recent study posted to the bioRxiv* preprint server, researchers investigated the biophysical fitness landscape of the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant.
In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.
In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the impact of an amyloidogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein fragment named SFYVYSRVK (SK9) on the α-synuclein (aS) monomers and fibrils, a potential risk factor for Parkinson’s disease.
In a recent study posted to the medRxiv* preprint server, researchers assessed the effect of changes in the abdominal well-being and physique on coronavirus disease 2019 (COVID-19) severity using magnetic resonance imaging (MRI).
The innate immune system plays a crucial role in regulating host-microbe interactions, and especially in providing protection against pathogens that invade the mucosa.
Melanoma patients receiving therapy that helps their immune system kill cancer cells respond to treatment differently depending on the types of microbes in their gut, and new research suggests the microorganisms hindering therapy have more influence than the beneficial ones.